Kimberly Westrich’s Post

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from March and April 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #ISPORAnnual

Association of the British Pharmaceutical Industry This report highlights the impact of NHS-industry partnerships on patient outcomes. Research shows that hospitals collaborating with industry are significantly more aligned with NICE recommendations for prescribing medicines, leading to better patient care. #NHS #healthcare #partnerships #research #abpi

The age-old debate of price versus product quality continues to shape the pharmaceutical industry’s competitive landscape. As healthcare costs soar and patients demand more affordable options, pharmaceutical companies find themselves at a crossroads. Should they focus on developing innovative, high-quality products regardless of cost, or should they prioritize competitive pricing to capture market share? This article delves deep into the multifaceted factors that influence this crucial decision and explores its implications for patients, healthcare providers, and the pharmaceutical industry as a whole. https://lnkd.in/ehUYsed

Have you registered for our upcoming webinar on key insights from recent payer and industry studies on the EU Joint Clinical Assessment?

Kimberly Westrich (Chief Strategy Officer, National Pharmaceutical Council) shares her highlights in US healthcare value and access from July and August 2024. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #valueassessment #inflationreductionact

Curious about how the EU Joint Clinical Assessment (JCA) will impact market access? Our upcoming webinar dives deep into findings from our latest industry study, revealing how pharmaceutical companies and payers are gearing up for this major regulation. From preparation insights to payer perspectives, gain actionable takeaways to navigate the JCA with confidence. Register now to secure your spot: skp.link/aibx #BetterMarketAccess #EUJCA #SimonKucher #JointClinicalAssessment

Curious about how the EU Joint Clinical Assessment (JCA) will impact market access? Our upcoming webinar dives deep into findings from our latest industry study, revealing how pharmaceutical companies and payers are gearing up for this major regulation. From preparation insights to payer perspectives, gain actionable takeaways to navigate the JCA with confidence. Register now to secure your spot: skp.link/aibx #BetterMarketAccess #EUJCA #SimonKucher #JointClinicalAssessment

Don’t forget to join David Alderson, Diana Brixner, Department of Pharmacotherapy, University of Utah College of Pharmacy, USA, Chris Teale, TealeHeath and Sam Mettam, Jazz Pharmaceuticals at #ISOPRAnnual today at 8am, as we meet to discuss and highlight the consequences of the Inflation Reduction Act and Joint Clinical Assessment and the revision of the EU Pharmaceutical Legislation on healthcare systems and R&D. #healtheconomics #healthcare #marketaccess

Curious about how the EU Joint Clinical Assessment (JCA) will impact market access? Our upcoming webinar dives deep into findings from our latest industry study, revealing how pharmaceutical companies and payers are gearing up for this major regulation. From preparation insights to payer perspectives, gain actionable takeaways to navigate the JCA with confidence. Register now to secure your spot: skp.link/aibx #BetterMarketAccess #EUJCA #SimonKucher #JointClinicalAssessment

💡 Handling Price Objections in Pharmaceutical Sales: Turning Challenges into Opportunities! 💊 In pharmaceutical sales, price objections are common, but they don’t have to be a roadblock. 🚧 The key is shifting the conversation from cost to value, focusing on patient outcomes, clinical efficacy, and long-term benefits. Here’s a quick guide on how to respond effectively when healthcare providers express concern about the price. your feedback is invaluable. 💭 #MedicalRep #PharmaceuticalSales #SalesStrategy #CustomerObjections #LinkedInLearning